Clara Perrone
Overview
Explore the profile of Clara Perrone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
35
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pomella S, Cassandri M, DArchivio L, Porrazzo A, Cossetti C, Phelps D, et al.
Nat Commun
. 2023 Dec;
14(1):8373.
PMID: 38102140
Rhabdomyosarcomas (RMS) are pediatric mesenchymal-derived malignancies encompassing PAX3/7-FOXO1 Fusion Positive (FP)-RMS, and Fusion Negative (FN)-RMS with frequent RAS pathway mutations. RMS express the master myogenic transcription factor MYOD that, whilst...
2.
Perrone C, Pomella S, Cassandri M, Pezzella M, Giuliani S, Gasperi T, et al.
Front Cell Dev Biol
. 2023 Feb;
11:1061570.
PMID: 36755974
Rhabdomyosarcoma (RMS) is a pediatric myogenic soft tissue sarcoma that includes fusion-positive (FP) and fusion-negative (FN) molecular subtypes. FP-RMS expresses PAX3-FOXO1 fusion protein and often shows dismal prognosis. FN-RMS shows...
3.
Perrone C, Pomella S, Cassandri M, Pezzella M, Milano G, Colletti M, et al.
Front Oncol
. 2022 May;
12:835642.
PMID: 35574376
Rhabdomyosarcoma (RMS) is a pediatric myogenic soft tissue sarcoma. The Fusion-Positive (FP) subtype expresses the chimeric protein PAX3-FOXO1 (P3F) while the Fusion-Negative (FN) is devoid of any gene translocation. FP-RMS...
4.
Perrone C, Pomella S, Cassandri M, Braghini M, Pezzella M, Locatelli F, et al.
Int J Mol Sci
. 2020 Nov;
21(22).
PMID: 33182556
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of children and adolescents. The fusion-positive (FP)-RMS variant expressing chimeric oncoproteins such as PAX3-FOXO1 and PAX7-FOXO1 is at high risk. The...
5.
Romanelli A, Stazi G, Fioravanti R, Zwergel C, Di Bello E, Pomella S, et al.
ACS Med Chem Lett
. 2020 May;
11(5):977-983.
PMID: 32435414
Since the histone modifying enzymes EZH2 and HDACs control a number of epigenetic-dependent carcinogenic pathways, we designed the first-in-class dual EZH2/HDAC inhibitor displaying (sub)micromolar inhibition against both targets. When tested...